Choisissez votre pays / Select your country

Ninalia NIPT The prenatal trisomy screening test based on maternal blood sample

Eurofins Biomnis and Non-Invasive Prenatal screening Test for trisomies 13, 18 and 21 (NIPT)

NIPT is an innovative genetic screening test for detecting the main fetal aneuploidies like Down syndrome (trisomy 21), Edwards’ syndrome (trisomy 18) or Patau syndrome (trisomy 13) in pregnant women at risk from these pathologies.


Today, this test also makes it possible to screen for other rarer chromosome abnormalities : autosomal abnormalities, deletions and duplications greater than 7 megabases (karyotype-equivalent resolution)

Several test options are available:

  • Ninalia 3 (NIPT) : Trisomies 21, 18 et 13
  • Ninalia 5 (NIPT) : Trisomies 21, 18 et 13 + fetal gender determination + sex chromosomes aneuploidies
  • Ninalia Genomewide (NIPT) : all autosomes + chromosomal imbalance greater than 7Mb Ninalia
  • Genomewide Complete (NIPT) : all autosomes + chromosomal imbalance greater than 7Mb + sex chromosomes aneuploidies + fetal gender determination

The non-invasive screening test uses cell-free DNA thanks to a sampling of maternal blood. It is without risk to fœtus.

The non-invasive screening test has much greater sensitivity and specificity than serum marker screening.

Although NIPT is really sensitive and specific, it is classified as a screening option for women at increased risk of trisomies 13, 18 or 21. In case of positive result, an invasive diagnostic procedure such as amniocentesis will confirm the diagnosis.

In many cases, NIPT means that invasive sampling can be dispensed with, thus reducing the associated risk of losing the foetus.*

Eurofins Biomnis follows the International recommendations of the American Congress of Obstetricians and Gynecologists (ACOG) and the Society for Maternal–Fetal Medicine (SMFM).

Geneticists who are qualified in prenatal diagnosis and responsible for Eurofins Biomnis tests are available to you as the prescriber to provide the best possible support in the implementation of this genetic test.

Advantages of Ninalia NIPT by Eurofins Biomnis

Know more on Eurofins Biomnis expertise in foetal biochemistry and prenatal diagnostics.

Maternal Serum Markers (MSM) Karyotype
SNPs Array

* Non-invasive prenatal testing of trisomies 13, 18 and 21 could make 95% of invasive tests, with an associated risk of miscarriage of around 0.5 to 1%, redundant (source: French National College of Gynaecologists and Obstetricians (CNGOF).

Eurofins Biomnis and NIPT Eurofins Biomnis and Non-Invasive Prenatal screening Test for trisomies 13, 18 and 21 (NIPT)

Vous avez refusé de partager votre position.
Désolé. Nous n'arrivons pas à savoir où vous êtes...
Il faut nous autoriser à voir votre position...
Votre navigateur ne possède pas cette fonctionnalité.

Partner laboratories

out of laboratories in total out of laboratories in total